Fortitude Targets AxSpA with Novel T-Cell Antibody

WALTHAM, MA – April 07, 2026 – Fortitude Biomedicines, a biopharmaceutical company specializing in next-generation immunotherapies, has announced its lead program: a first-in-class T-cell targeting bispecific antibody aimed at Axial Spondyloarthritis (AxSpA), a debilitating inflammatory disease affecting millions worldwide. The announcement, which includes the strategic appointment of rheumatologist Dr. Rahul Patel to lead clinical development, signals a significant step for the company as it prepares to tackle a condition where over half of patients fail to achieve adequate relief with existing treatments.

With promising preclinical data and a clear path toward a 2027 clinical trial, Fortitude is entering a dynamic market with a technology designed to offer new hope for a large and underserved patient population.

A Chronic Condition with a Glaring Unmet Need

Axial Spondyloarthritis is a chronic, progressive inflammatory disease that primarily affects the axial skeleton, including the spine and sacroiliac joints. Affecting more than 1.8 million people in the United States and over 50 million globally, the disease typically strikes adults under the age of 40. Patients endure persistent inflammatory back pain, debilitating stiffness, and enthesitis—inflammation where tendons and ligaments attach to bone. If not effectively controlled, AxSpA can lead to irreversible structural damage, including the fusion of vertebrae, resulting in long-term functional impairment and a severely diminished quality of life.

The global market for AxSpA therapies, valued at nearly $4.7 billion, underscores the scale of the disease. However, a significant treatment gap persists. The current standard of care begins with non-steroidal anti-inflammatory drugs (NSAIDs). For patients who don't respond, physicians turn to biologic disease-modifying antirheumatic drugs (bDMARDs), such as TNF inhibitors and IL-17 inhibitors. While these biologics have been transformative for many, their effectiveness is far from universal. Clinical data consistently shows that only 40-50% of patients achieve a significant clinical response (defined as ASAS40), and a mere 17.6% are able to sustain long-term remission. This leaves a vast portion of the patient population struggling with persistent symptoms.

“With more than 50 percent of AxSpA patients unable to achieve adequate disease control, there continues to be a large unmet need in management of this disease,” said Dr. Jesse Chen, President and CEO of Fortitude, in the company's announcement. This statement is strongly supported by real-world evidence, where up to 40% of patients either fail to respond to initial biologic therapy or lose their response over time. This challenge has given rise to the concept of "difficult-to-treat AxSpA," a patient segment that represents a critical unmet need and the primary target for next-generation therapies.

Fortitude’s Two-Pronged Attack on Disease

Fortitude is positioning itself to address this need with a dual-platform strategy focused on precision and potency. The lead program for AxSpA leverages a T-cell targeting bispecific antibody, a sophisticated biologic engineered to perform a highly specific task. Unlike traditional immunosuppressants that broadly dampen the immune system, this bispecific antibody is designed to selectively modulate the activity of disease-driving T-cells, which are key players in the inflammatory cascade of autoimmune conditions.

The company reports that its lead candidate has demonstrated "selective and durable suppression of disease-driven T-cell signaling pathways" in preclinical animal models. The goal is to achieve a higher bar of efficacy by precisely neutralizing the pathological immune response while leaving the healthy functions of the immune system largely intact. This targeted approach could potentially offer improved outcomes with a more favorable safety profile compared to broader immunosuppressive agents.

Beyond its lead program, Fortitude is developing a proprietary platform called GLUE-DAC™, an innovative fusion of two powerful technologies: Antibody-Drug Conjugates (ADCs) and molecular glue degraders. Traditionally, ADCs act like guided missiles, delivering a toxic payload to a specific cell type, such as a cancer cell. Fortitude's platform replaces the conventional toxic payload with a molecular glue—a small molecule that forces the degradation of a specific disease-causing protein within the target cell. This catalytic mechanism, where one molecule of the drug can trigger the destruction of many protein molecules, has the potential to overcome drug resistance, improve the therapeutic window, and attack proteins previously considered "undruggable."

This dual strategy of developing both targeted biologics for autoimmunity and a versatile ADC platform for oncology and other diseases positions Fortitude to tackle complex conditions from multiple angles, building a diversified and robust pipeline.

Strategic Moves in a Competitive Field

Entering the crowded and competitive autoimmune market requires more than just novel science; it demands sharp strategic execution and substantial financial backing. Fortitude appears to be making calculated moves on both fronts. The company recently launched with a $13 million seed financing round co-led by K2 Bio Partners and Shanghai Healthcare Angel Capital, providing the necessary capital to advance its lead AxSpA program through investigational new drug (IND)-enabling studies and toward its planned clinical entry in the first half of 2027.

To guide this critical clinical journey, Fortitude has appointed Dr. Rahul Patel as Senior Vice President of Clinical Development. As a board-certified rheumatologist and experienced drug developer, his expertise is crucial for navigating the complex trial landscape for AxSpA and engaging with regulatory agencies. His appointment reinforces the company's commitment to clinical excellence and a patient-centric approach.

“I am pleased to join Fortitude, to coordinate with exceptional team members and to advance an innovative pipeline of therapeutics,” said Dr. Patel. “There remains a significant unmet need in rheumatology, including in AxSpA, for therapies that can advance the field further and potentially offer a higher bar of efficacy.”

Fortitude’s T-cell targeting approach joins a broader industry trend toward precision immunotherapies. While competitors explore CAR-T therapies and other cell-based treatments for autoimmune diseases like lupus and myositis, Fortitude's focus on a bispecific antibody for the specific challenges of AxSpA carves out a distinct niche. The success of this program would not only provide a vital new option for patients suffering from this chronic condition but also serve as a powerful validation of the company's underlying scientific platforms.